Lifeward Ltd

Aktienanalyse zu Lifeward Ltd (LFWD)

$5.810

+0.071 (+1.22%)Zum Schluss

Loading chart…
Hoch
5.964
Eröffnung
5.650
Volumengewichteter Durchschnittskurs
5.81
Volumen
5.03K
Marktkap.
—
Tief
5.650
Umsatz
29.19K
EV/EBITDA, TTM
-0.85

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

golifeward.com

KI-Analyse of Lifeward Ltd (LFWD)

Halten

ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Lifeward Ltd (LFWD) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -2.96.

Erwartetes KGV

Überbewertet
5J-Durchschnitt P/E
-2.96
Aktuelles P/E
0.00
Überbewertet
-1.37
Unterbewertet
-4.55

Erwartetes EV/EBITDA

Unterbewertet
5J-Durchschnitt EV/EBITDA
-0.08
Aktuelles EV/EBITDA
-0.85
Überbewertet
0.50
Unterbewertet
-0.66

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
2.58
Aktuelles P/S
0.39
Überbewertet
5.94
Unterbewertet
-0.77

Alphio-AI-Kursszenarien für LFWD

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%LFWD

$1.83

Szenariopreis

B

Basis

Basis · 50%LFWD

$1.53

Szenariopreis

B

Bärisch

Bärisch · 25%LFWD

$1.30

Szenariopreis

Event-Zeitleiste

2026-10-01 (ET)

10:00:00

Rewalk Robotics LTD Trading Halted Due to Volatility

2026-08-31 (ET)

16:30:00

Lifeward Appoints Josh Hexter as Interim CEO

2026-08-03 (ET)

09:30:00

Company Not Selling 2.07M Ordinary Shares

2026-05-19 (ET)

08:30:00

Lifeward Appoints Keith Rose as Chief Medical Officer

2026-04-27 (ET)

17:10:00

Lifeward Files to Sell 7.26M Ordinary Shares

News

LFWD FAQ – beantwortet von Alphio AI

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln